TY - JOUR
T1 - The Mnks are novel components in the control of TNFα biosynthesis and phosphorylate and regulate hnRNP A1
AU - Buxadé, Maria
AU - Parra, Josep L.
AU - Rousseau, Simon
AU - Shpiro, Natalia
AU - Marquez, Rodolfo
AU - Morrice, Nick
AU - Bain, Jenny
AU - Espel, Enric
AU - Proud, Christopher G.
N1 - Funding Information:
We thank J. Comas (Universitat de Barcelona) for expert assistance in flow cytometry analysis; M. Kleijn, G. Scheper (both University of Dundee), and S. MacKenzie (Universitat de Barcelona) for technical advice; I. Puga (Universitat de Barcelona) and M. Wilson (University of Dundee) for technical help; M. Peggie (MRC Protein Phosphorylation Unit, Dundee) for the hnRNP A1 clone; and D. Lamont and K. Beattie (University of Dundee) for MALDI-TOF MS analyses. This research was supported by the Fondo de Investigación Sanitaria (E.E.), Ministerio de Educación y Cultura (M.B.), the European Union (M.B., E.E., and C.G.P.) and the Medical Research Council (C.G.P.).
PY - 2005/8
Y1 - 2005/8
N2 - Posttranscriptional regulatory mechanisms control TNFα expression through AU-rich elements in the 3′UTR of its mRNA. This is mediated through Erk and p38 MAP kinase signaling, although the mechanisms involved remain poorly understood. Here, we show that the MAP kinase signal-integrating kinases (Mnks), which are activated by both these pathways, regulate TNFα expression in T cells via the 3′UTR. A selective Mnk inhibitor or siRNA-mediated knockdown of Mnk1 inhibits TNFα production in T cells, whereas Mnk1 overexpression enhances expression of a reporter construct containing the TNFα 3′UTR. We identify ARE binding proteins that are Mnk substrates, such as hnRNP A1, which they phosphorylate at two sites in vitro. hnRNP A1 is phosphorylated in response to T cell activation, and this is blocked by Mnk inhibition. Moreover, Mnk-mediated phosphorylation decreases binding of hnRNP A1 to TNFα-ARE in vitro or TNFα-mRNA in vivo. Therefore, Mnks are novel players in cytokine regulation and potential new targets for anti-inflammatory therapy.
AB - Posttranscriptional regulatory mechanisms control TNFα expression through AU-rich elements in the 3′UTR of its mRNA. This is mediated through Erk and p38 MAP kinase signaling, although the mechanisms involved remain poorly understood. Here, we show that the MAP kinase signal-integrating kinases (Mnks), which are activated by both these pathways, regulate TNFα expression in T cells via the 3′UTR. A selective Mnk inhibitor or siRNA-mediated knockdown of Mnk1 inhibits TNFα production in T cells, whereas Mnk1 overexpression enhances expression of a reporter construct containing the TNFα 3′UTR. We identify ARE binding proteins that are Mnk substrates, such as hnRNP A1, which they phosphorylate at two sites in vitro. hnRNP A1 is phosphorylated in response to T cell activation, and this is blocked by Mnk inhibition. Moreover, Mnk-mediated phosphorylation decreases binding of hnRNP A1 to TNFα-ARE in vitro or TNFα-mRNA in vivo. Therefore, Mnks are novel players in cytokine regulation and potential new targets for anti-inflammatory therapy.
UR - http://www.scopus.com/inward/record.url?scp=23844516065&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2005.06.009
DO - 10.1016/j.immuni.2005.06.009
M3 - Article
C2 - 16111636
AN - SCOPUS:23844516065
SN - 1074-7613
VL - 23
SP - 177
EP - 189
JO - Immunity
JF - Immunity
IS - 2
ER -